RxDoctor Payments Data

Harry Roach, MD

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Metairie, LANPI 1396745089

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,246 of the $2,930 with a category attached, or 76.7%. Silk Road Medical, Inc. accounts for 63.7% of it on its own, with 16 other manufacturers making up the rest. That places this record below the midpoint for thoracic surgery (cardiothoracic vascular surgery) clinicians in LA, where the typical reported total is $4,896.

$2,930in general payments, 2019–2025

Across 40 payments — averaging $73.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$2K
  • Boston Scientific$145
  • Baxter Healthcare$144
  • Neurocrine Biosciences, Inc.$126
  • Pfizer$121
  • Edwards Lifesciences$113
  • plus $416 from 11 others

What the payments were for

  • Travel & lodging$68423%
  • Food & beverage$2,24677%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,930 in reported general payments places this provider in the 35th percentile of 75 thoracic surgery (cardiothoracic vascular surgery) providers in Louisiana.

See all thoracic surgery (cardiothoracic vascular surgery) providers in Louisiana

Medicare billing

Part B allowed, 2024
$76,021
Medicare patients
162
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$14,269
Cilostazol81$1,548
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen70$756
Triamcinolone Acetonide27$462
Potassium Chloride33$433
Bumetanide24$424
Gabapentin30$355
Spironolactone27$314
ClopidogrelClopidogrel Bisulfate33$297
Pentoxifylline21$297
Methylprednisolone20$158
Furosemide41$132
Cephalexin17$84
Metoprolol Tartrate21$67
Amlodipine Besylate11$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$14,26911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 75 thoracic surgery (cardiothoracic vascular surgery) providers in Louisiana.

Other thoracic surgery (cardiothoracic vascular surgery) in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →